Assessment of sympathetic reinnervation of the kidney allograft with 123I-MIBG scintigraphy. (RENnervate study).

Completed

• Conditions: Regrowth of sympathetic nerves in the transplanted kidney; 10038430

• Registration Number: NL-OMON39698
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

Negative control group: recently transplanted patients (n<=6)
- renal graft in situ for 0-6 weeks
- a measured creatinine clearance *50 ml/min
- having at least one native kidney in situ;When the negative control group with normal kidney function will show 123I-MIBG activity, an additional negative control group is studied, consisting of n<=6 recently transplanted anuric patients
- renal graft in situ for 0-6 weeks
- anuria due to delayed graft function or non-functioning graft (diuresis of maximum 150ml/day)
- having at least one native kidney in situ;Recently transplanted patients (n<=6)
- renal graft in situ for 6-18 months at time of measurement
- a measured creatinine clearance *50 ml/min
- having at least one native kidney in situ;Approximately 5 year renal transplant survivors (n<=6)
- renal graft in situ for > 4* < 7 years at time of measurement
- a measured creatinine clearance *50 ml/min
- having at least one native kidney in situ;Long term graft survivors (n<=6)
- renal graft in situ for >10 years at time of measurement
- a measured creatinine clearance *50 ml/min
- having at least one native kidney in situ

Exclusion Criteria

- pregnancy
- unable to give informed consent
- absolute indication for alpha and beta-blocking agents
- allergy for iodine

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To compare allograft sympathetic reinnervation by 123I-MIBG washout rates<br /><br>between patients with a recent transplantation (6-18 months), patients with an<br /><br>allograft in situ for > 4* and <7 years and patients who have a kidney<br /><br>transplantant >10 years. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>